Polycaprolactone Nanoparticles Boost Licofelone Transdermal Delivery for Osteoarthritis: In Vitro Characterization, Ex Vivo Permeability, and In Vivo Efficacy
Open Access
- 29 December 2025
- journal article
- research article
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (1) , 77
Abstract
Purpose: Polycaprolactone nanoparticles (PCLNPs) are biodegradable carriers widely investigated for drug delivery applications. Their hydrophobic nature and high encapsulation efficiency make them ideal for sustained drug release. This study aimed to encapsulate licofelone (LF), a dual COX/5-LOX inhibitor, within PCLNPs to enhance its therapeutic efficacy for osteoarthritis treatment through transdermal administration. Methods: LF loaded PCLNPs were formulated using the nanoprecipitation method. A 2 3 full factorial design was employed by varying PCL (100 or 150 mg), PVA (150 or 300 mg), and SDC (10 or 20 mg) at two levels each. The optimum formula was F8, consisting of 150 mg PCL, 300 mg PVA, and 20 mg SDC. Results: F8 formulation exhibited a spherical shape with a particle size (PS) of 269.3 ± 1.90 nm, an encapsulation efficiency (EE%) of 89 ± 0.56%, a polydispersity index (PDI) of 0.21 ± 0.02, and a zeta potential (ZP) of -27.85 ± 0.07 mV. The F8 gel exhibited a sustained-release profile, with drug permeation across excised rat skin 2.47-fold higher than that of the LF gel ( n = 3, p < 0.05). In vivo evaluation revealed significant chondroprotective and regenerative effects in a monoiodoacetate (MIA)-induced osteoarthritis rat model. F8 gel suppressed the release of inflammatory and pain mediators (5-LOX, COX, LTB 4 , and PGE2) and serum cartilage degradation products (CTX-II and COMP) after 10 days of treatment. Histological evaluation further confirmed its ability to prevent cartilage surface depletion and matrix loss. Conclusion: The optimized F8 gel achieved sustained LF release for approximately 20 h, enhanced ex vivo permeation by 2.47-fold relative to LF gel, and significantly reduced inflammatory mediators and cartilage degradation markers in vivo, highlighting its potential as a promising transdermal therapy for osteoarthritis management. GraphicalKeywords
Funding Information
- 6 October University
This publication has 71 references indexed in Scilit:
- Polysaccharide Based Biomaterials for Dermal Applications2022
- Intra-articular targeting of nanomaterials for the treatment of osteoarthritisActa Biomaterialia, 2019
- Polycaprolactone Based Nanoparticles Loaded with Indomethacin for Anti-Inflammatory Therapy: From Preparation to Ex Vivo StudyPharmaceutical Research, 2017
- Injectable long acting chitosan/tripolyphosphate microspheres for the intra-articular delivery of lornoxicam: Optimization and in vivo evaluationCarbohydrate Polymers, 2016
- Stabilization of chitosan/hyaluronan colloidal polyelectrolyte complexes in physiological conditionsCarbohydrate Polymers, 2015
- Design of Nanosuspensions and Freeze-Dried PLGA Nanoparticles as a Novel Approach for Ophthalmic Delivery of PranoprofenJournal of Pharmaceutical Sciences, 2014
- Highly Loaded, Sustained-Release Microparticles of Curcumin for ChemopreventionJournal of Pharmaceutical Sciences, 2011
- Role of the stereosequences of poly(vinyl alcohol) in the rheological properties of syndiotacticity‐rich poly(vinyl alcohol)/water solutionsJournal of Applied Polymer Science, 2003
- In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1? synthesisArthritis & Rheumatism, 2001
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976